Abstract
Type 1 diabetes mellitus (T1DM) is an autoimmune disease, due to the immune-mediated destruction of pancreatic -cells, whose incidence has been steadily increasing during the last decades. Insulin replacement therapy can treat T1DM, which, however, is still associated with substantial morbidity and mortality. For this reason, great effort is being put into developing strategies that could eventually prevent and/or cure this disease. These strategies are mainly focused on blocking the immune system from attacking -cells together with functional islet restoration either by regeneration or transplantation. Recent experimental evidences suggest that TNFrelated apoptosis-inducing ligand (TRAIL), which is an immune system modulator protein, could represent an interesting candidate for the cure for T1DM and/or its complications. Here we review the evidences on the potential role of TRAIL in the management of T1DM.
Keywords: Autoimmune diabetes mellitus, TRAIL, apoptosis, signal transduction
Current Pharmaceutical Design
Title:Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus
Volume: 18 Issue: 35
Author(s): Stella Bernardi, Alessia Norcio, Barbara Toffoli, Giorgio Zauli and Paola Secchiero
Affiliation:
Keywords: Autoimmune diabetes mellitus, TRAIL, apoptosis, signal transduction
Abstract: Type 1 diabetes mellitus (T1DM) is an autoimmune disease, due to the immune-mediated destruction of pancreatic -cells, whose incidence has been steadily increasing during the last decades. Insulin replacement therapy can treat T1DM, which, however, is still associated with substantial morbidity and mortality. For this reason, great effort is being put into developing strategies that could eventually prevent and/or cure this disease. These strategies are mainly focused on blocking the immune system from attacking -cells together with functional islet restoration either by regeneration or transplantation. Recent experimental evidences suggest that TNFrelated apoptosis-inducing ligand (TRAIL), which is an immune system modulator protein, could represent an interesting candidate for the cure for T1DM and/or its complications. Here we review the evidences on the potential role of TRAIL in the management of T1DM.
Export Options
About this article
Cite this article as:
Bernardi Stella, Norcio Alessia, Toffoli Barbara, Zauli Giorgio and Secchiero Paola, Potential Role of TRAIL in the Management of Autoimmune Diabetes Mellitus, Current Pharmaceutical Design 2012; 18 (35) . https://dx.doi.org/10.2174/138161212803530925
DOI https://dx.doi.org/10.2174/138161212803530925 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Editorial [Hot Topic: Stroke Prevention (Guest Editors: T. Tatlisumak, K. Rantanen and M. Fisher)]
Current Drug Targets Chemical and Physical Aspects of the Edible Fractions and Seeds of Jamelao (Syzygium cumini, L. Skeels)
The Natural Products Journal Recent Advances in Antiarrhythmic Drug Treatment of Atrial Fibrillation
Recent Patents on Cardiovascular Drug Discovery Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?
Current Vascular Pharmacology Mild Mitochondrial Uncoupling as a Therapeutic Strategy
Current Drug Targets Carotid Artery Atherosclerosis: What is the Evidence for Drug Action?
Current Pharmaceutical Design Neck Circumference and its Correlation to Other Anthropometric Parameters and Finnish Diabetes Risk Score (FINDRISC)
Current Diabetes Reviews Drug Interactions During Periodontal Therapy in HIV-Infected Subjects
Mini-Reviews in Medicinal Chemistry PACAP in the Glucose and Energy Homeostasis: Physiological Role and Therapeutic Potential
Current Pharmaceutical Design Evolving Larger: Dosing Anti-Tuberculosis (TB) Drugs in an Obese World
Current Pharmaceutical Design Methylglyoxal, A Metabolite Increased in Diabetes is Associated with Insulin Resistance, Vascular Dysfunction and Neuropathies
Current Drug Metabolism Targeting Farnesoid-X-Receptor: From Medicinal Chemistry to Disease Treatment
Current Medicinal Chemistry Bile Acids and Farnesoid X Receptor: Novel Target for the Treatment of Diabetic Cardiomyopathy
Current Protein & Peptide Science A<sub>3</sub> Adenosine Receptor: A Plausible Therapeutic Target for Cardio-Protection in Diabetes
Recent Patents on Cardiovascular Drug Discovery Treatment of ‘Diabesity’: Beyond Pharmacotherapy
Current Drug Targets Symptomatic Treatment of Chronic Neuropathic Pain with Gabapentin Clinical Practice and Research Prospective
Current Neuropharmacology Endothelial Dysfunction in Diabetes: The Role of Protein Kinase C
Vascular Disease Prevention (Discontinued) Neuron-glia Interaction as a Possible Pathophysiological Mechanism of Bipolar Disorder
Current Neuropharmacology Advanced Glycation: How are we Progressing to Combat this Web of Sugar Anomalies in Diabetic Nephropathy
Current Pharmaceutical Design Editorial (Hot Topic: New Insights into Insulin Resistance, Cardiovascular Diseases and Oxidative Stress: Pathophysiological and Clinical Consequences)
Current Pharmaceutical Design